Abstract
Leukemia inhibitory factor (lif) is a potent survival factor for motoneurons in cell culture and in vivo. The authors screened 104 patients with ALS and 338 control subjects for mutations in the LIF gene. In four ALS patients, but in no control subject, a G-to-A point mutation at position 3400 was identified, which leads to an amino acid exchange of valine to methionine at position 64 of the mature lif protein. This region of the lif protein (AB loop) interacts with the lif receptor. The authors suggest that LIF could act as a modifier gene which, in combination with other genetic predispositions, might lead to motoneuron disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Amyotrophic Lateral Sclerosis / genetics*
-
Amyotrophic Lateral Sclerosis / physiopathology*
-
Female
-
Growth Inhibitors*
-
Humans
-
Interleukin-6*
-
Leukemia Inhibitory Factor
-
Leukemia Inhibitory Factor Receptor alpha Subunit
-
Lymphokines*
-
Male
-
Middle Aged
-
Polymerase Chain Reaction
-
Polymorphism, Single-Stranded Conformational
-
Receptors, Cytokine / genetics*
-
Receptors, OSM-LIF
Substances
-
Growth Inhibitors
-
Interleukin-6
-
LIF protein, human
-
LIFR protein, human
-
Leukemia Inhibitory Factor
-
Leukemia Inhibitory Factor Receptor alpha Subunit
-
Lymphokines
-
Receptors, Cytokine
-
Receptors, OSM-LIF